A novel, potent, semisynthetic pneumocandin, L-733,560, was Chem. 37:222-225, 1994). Glucan synthesis catalyzed by a crude membrane fraction prepared from the S. cerevisiae mutant R560-1C was resistant to inhibition by L-733,560. The nearly 50-fold increase in the 50% inhibitory concentration against glucan synthase was commensurate with the increase in whole-cell resistance. R560-1C was cross-resistant to other inhibitors of C. albicans 1,3-p-D-glucan synthase (aculeacin A, dihydropapulacandin, and others) but not to compounds with different modes of action. Genetic analysis revealed that enzyme and whole-cell pneumocandin resistance was due to a single mutant gene, designated etgl-l (echinocandin target gene 1), which was semidominant in heterozygous diploids. The etgl-l mutation did not confer enhanced ability to metabolize L-733,560 and had no effect on the membrane-bound enzymes chitin synthase I and squalene synthase. Alkali-soluble (B-glucan synthesized by crude microsomes from R560-1C was indistinguishable from the wild-type product. 1,3-I-D-Glucan synthase activity from R560-1C was fractionated with NaCl and Tergitol NP-40; reconstitution with fractions from wild-type membranes revealed that drug resistance is associated with the insoluble membrane fraction. We propose that the etgl-l mutant gene encodes a subunit of the 1,3-0-D-glucan synthase complex.
resistant, but the mutations did not affect aculeacin-sensitive polysaccharide synthesis in a regenerating spheroplast system or an in vitro 1,3-0-D-glucan synthesis assay. While limited inhibition of S. cerevisiae in vitro P-glucan synthesis by aculeacin has been described (62) , no other inhibitor of the C. albicans enzyme (echinocandin B, cilofungin, papulacandin) has been shown to inhibit S. cerevisiae activity, and none of the mutants isolated to date has drug-resistant enzyme activity.
We describe here the use of the novel semisynthetic pneumocandin L-733,560 to isolate an S. cerevisiae mutant with resistant P-glucan synthase activity. This mutant, R560-1C, is specifically resistant to inhibitors of 1,3-3-D-glucan synthesis such as the pneumocandins, echinocandins, and papulacandins. Resistance to L-733,560 as measured in the in vitro reaction is commensurate with whole-cell resistance, and both phenotypes cosegregate in genetic crosses. The mutation defines a new locus, which we have named ETG1 for echinocandin target gene 1. Other properties of the enzyme (substrate binding and specific activity) and characteristics of the product synthesized in vitro are unaffected by the mutation. Fractionation experiments with crude membranes from R560-1C and its wild-type parent show that the etgl-1 mutation affects the insoluble fraction believed to contain the catalytic subunit (29) .
Our results suggest that ETG1 encodes a subunit of 1,3-p-Dglucan synthase.
MATERUILS AND METHODS
Strains and libraries. S. cerevisiae W303-1A (MATa ade2-1 canl-100 his3-11,15 leu2-3,112 trpl-1 ura3-1) and W303-1B (MA Ta ade2-1 canl-100 his3-11,15 leu2-3,112 trpl-1 ura3-1) were provided by R. Rothstein (59) . X2180-1A (MATa) and X2180-1B (MATa) were obtained from the American Type Culture Collection. Escherichia coli DHSat from Bethesda Research Laboratories was used as a host for recombinant plasmids. An S. cerevisiae genomic library constructed from DNA partially digested with Sau3AI and ligated into YEp24 (18) was obtained from S. Parent (Merck & Co., Inc).
Antifungal compounds and assays. Pneumocandins L-733, 560 (12) , L-731,373 (12) , and pneumocandin Bo (49) , as well as L-687,781 (61) , sphingofungin B (26) , mevinolin (1) , and the zaragosic acids A and B (8) , were synthesized or isolated at Merck Research Laboratories, Rahway, N.J. Fluconazole (39) and ketoconazole were obtained from Janssen, and terbinafine (SF86-327) (41) was obtained from Sandoz. Aculeacin A (37) was from Toyo Jozo, and tetrahydroechinocandin B (31) Transformants were cured of plasmid DNA by growth in uracil-supplemented minimal medium followed by selection with 5-fluoroorotic acid (9) . Uracil auxotrophs were identified and tested for drug sensitivity. Plasmid DNA was isolated from clones by standard methods (53) , transformed into E. coli DH5a, and analyzed for inserts by digestion with restriction endonucleases (34) . To test for plasmid-dependent phenotypes, S. cerevisiae W303-1A was transformed as described with plasmids isolated from E. coli and assayed for drug resistance by the broth microdilution method.
Chitin and squalene synthase assays. Crude membrane fractions from W303-1A and R560-1C were assayed for chitin synthase I activity. Crude protein (750 ,ug) was pretreated with trypsin (Sigma) and incubated with 10 nCi of UDP-N-acetyl-D-[glucosamine-14C(U)] (>200 mCi/mmol; NEN), and then the product was harvested as described previously (17) . The IC50 for nikkomycin Z was measured by titrating the drug from 0.02 ,ug/ml to 5 ,ug/ml and calculating the percentage of inhibition of synthesis.
Squalene synthase activity was measured according to the method of Bergstrom et al. (8) . buffer (pH 7.5), with 1 mM NADPH, 5.5 mM MgCl2, 11 mM potassium fluoride, 3 mM dithiothreitol, 1 jig of terbinafine per ml, and 5 jiM farnesyl pyrophosphate (final specific activity, 1.1 X 106 dpm/nmol). After a 12-min incubation at 30°C, 1 volume of ethanol was added and squalene was extracted from the reaction mixture with 2 volumes of nheptane containing 1 jil of squalene per ml. Radioactivity in the organic phase of the extract was determined by liquid scintillation counting. Titration of zaragosic acid A from 0.02 nM to 1.8 nM against the enzyme from mutant and wild-type strains was used to determine the IC50.
Genetic analysis. Standard methods were used for mating, sporulation, tetrad dissection, and analysis of auxotrophic markers (53) .
High-performance liquid chromatography (HPLC) analysis of L-733,560. Standard in vitro glucan synthesis reaction mixtures with crude membrane fractions from R560-1C and W303-1A were prepared with L-733,560 added at a final concentration of 2 ,uM. After 150 min at 22°C, the samples were centrifuged at 100,000 X g for 1 h at 4°C and L-733,560 in the supernatants was quantitated essentially by the method of Hadju et al. (24) . Samples (25 jl) were injected onto a Zorbax RXC8 column equilibrated at 37°C and eluted at 1.2 ml/min with 60% methanol-32.4 mM acetic acid-25 mM triethylammonium phosphate (pH 2.9). The drug was detected by fluorescence (excitation, 224 nm; emission, 302 nm) and quantitated against a standard curve of L-733,560.
Fractionation of crude microsomes. Crude membranes from R560-1C and W303-1A were prepared and fractionated by the method of Kang et al. (29) . Cells grown to 7 x 105 cells per ml were harvested by centrifugation and broken with glass beads, and the crude membranes were extracted with Tergitol NP-40 and 2 M NaCl with (soluble fraction) and without (insoluble fraction) 20 jiM GTP--y-S. For reconstitution experiments, 25 jig of particulate fraction and 7.5 jig of soluble fraction were added to reaction mixtures with or without added L-733,560.
Gel filtration of product. Radiolabeled product was partially purified from glucan synthesis reaction mixtures by gel filtration. After synthesis, duplicate samples were combined, made alkaline by the addition of 0.25 volumes of 50% NaOH, and centrifuged for 1 min at 10,000 X g at 250C. The supernatant (200 plI) was chromatographed at 0.3 ml/min on a Superose 12 column (Pharmacia) with 150 mM NaOH as eluant. Fractions were collected, neutralized with 150 mM HCl, and counted. To calibrate the column, linear dextrans (Sigma) ranging in size from 9.3 kDa to 515 kDa were chromatographed under the same conditions and detected by the phenol-sulfuric acid method (22) . Curdlan, a linear 1,3-0-D-glucan with a size of ca.
450 glucose units isolated from Alcaligenes faecalis (Accurate Chemical & Scientific Corp., Westbury, N.Y.), was also used as a standard.
Product analysis. Peak fractions containing radiolabeled product from repeat runs on the Superose 12 column were pooled, dialyzed overnight at 40C against water, and dried under a vacuum. Over 90% of the radioactivity was recovered after dialysis. Samples were resuspended in 0.1 M acetate buffer (pH 5.0). One aliquot was treated with 2 U of laminarinase (Sigma) for 18 h at 370C (42); a duplicate aliquot without enzyme served as a control. A solution of NaOH (50%; 0.1 sample volume) was added, and the samples were sonicated for 15 min at 25°C before separation by gel filtration and scintillation counting as described. The fractions from the gel filtration column containing the radiolabeled digestion product were pooled, and an aliquot (50 ,il) was subjected to anion-exchange chromatography on a CarboPac PA1 column (Dionex Corporation, Sunnyvale, Calif.) equilibrated and eluted at ambient temperature with 8 mM NaOH at a flow rate of 1 ml/min. Carbohydrate in the effluent was detected by pulsed amperometry (sampling time [t] = 200 ms) with the following settings: E1 = 0.10 V (t1 = 500), E2 = 0.60 V (t2 = 100), and E3 = -0.60 V (t3 = 50 ms) (28) . A standard mixture of neutral and amino sugars was chromatographed under the same conditions. The profile of 3H-labeled material was determined by collecting fractions and counting with Scintiverse (Fisher Scientific), with a counting efficiency of 40%.
RESULTS
Activity of L-733,560 against S. cereisiae. Naturally occurring pneumocandins, echinocandins, and papulacandins have relatively weak antifungal activity against S. cerevisiae. Recent chemical efforts to improve upon the antifungal properties of the pneumocandins led to the synthesis of L-733,560, a dibasic water-soluble derivative of pneumocandin Bo (12) . Table 1 gives the MICs of L-733,560 and the natural products pneumocandin Bo, dihydropapulacandin (L-687,781), and aculeacin A against S. cerevisiae W303-1A and X2180-1A. L-733,560 is at least 16-fold more active against both strains than the natural products. After 48 h, samples from the MIC assay were spotted on drug-free agar plates to determine the minimum fungicidal concentration; wells with no visible growth failed to produce colonies. Against C. albicans, the minimum fungicidal concentration for L-733,560 (0.15 jig/ml) was sevenfold lower than the value for pneumocandin Bo (1.06 jig/ml). The significant potency of L-733,560 made this compound especially attractive as a selective agent. Inhibition of in vitro glucan synthesis. In C. albicans, the improved antifungal activity of L-733,560 was correlated with its increased potency against 1,3-13-D-glucan synthase (33) . We evaluated the activity of L-733,560 against S. cerevisiae glucan synthase in crude membranes from W303-1A and X2180-1A. Inhibition curves of the logarithm of the L-733,560 concentration versus the product formed (Fig. 1) show that synthesis was inhibited in a dose-dependent fashion, with a maximum of 90% inhibition at 50 p.M L-733,560, an IC50 of 1 1iM, and a linear portion spanning a nearly 100-fold range of drug concentrations, from 0.08 p.M to nearly 10 p.M. The reaction is also inhibited by pneumocandin Bo and L-687,781, but the estimated IC50 values were greater than 10 t.M for both compounds, with virtually no inhibition at concentrations below 1 p.M (data not shown). We examined the kinetics of L-733,560 inhibition (Fig. 2) . Typically, noncompetitive inhibitors give rise to lines which converge at the x axis, whereas the lines for a competitive inhibitor are parallel and those of a mixed inhibitor converge at a point where [S]/v is <0. The plot for L-733,560 inhibition is consistent with noncompetitive inhibition.
Isolation of R560-1C. The improved potency of L-733,560 compared with that of other 3-glucan synthesis inhibitors suggested that it might be useful as a selective agent for cloning S. cerevisiae target genes that confer antibiotic resistance when they are overexpressed. Three independent libraries of S. cerevisiae total genomic DNA were transformed into W303-1A, and 27 drug-resistant colonies were isolated. These clones were challenged with drug in a liquid MIC assay to estimate the level of resistance. One clone (R560-1) was at least 10-fold more resistant than the parent strain; the others were 2-to 4-fold more resistant. We examined the effect of plasmid loss on the drug resistance phenotype by selecting for spontaneous plasmid-free, uracil-requiring derivatives with 5-fluoroorotic acid and assaying them for sensitivity to L-733,560. Surprisingly, the phenotype of R560-1 was unchanged by the loss of plasmid (Fig. 3) . The twofold difference in resistance between strain R560-1 and the cured derivative R560-1C is within the experimental error. Plasmid DNA isolated from R560-1 failed to confer L-733,560 resistance when retransformed into W303-1A.
Specificity of resistance. A panel of known antifungal antibiotics with various modes of action were tested against R560-1C and W303-1A to determine the specificity of the resistance phenotype (Table 2) compounds tested, the sensitivities of R560-1C and W303-1A were equivalent. There was no change in the mutant's sensitivity to the chitin synthesis inhibitor nikkomycin Z or the glycosylation inhibitor tunicamycin. Sterol and fatty acid synthesis inhibitors such as the zaragosic acids, cerulenin, fluconazole, ketoconazole, mevinolin, and terbinafine produced similar zones of growth inhibition on both strains. We also observed no difference in sensitivity to antifungal agents which inhibit protein synthesis (cycloheximide), secretion (trifluoroperazine), sphingolipid biosynthesis (sphingofungin B), or 163 ) from 100 ,ug/ml to 0.20 ,ug/ml (final concentration) in SD medium with or without uracil. After 24 h at 30°C, the optical density at 600 nm was measured for each well. Growth relative to that of a drug-free control well was used to calculate the dose-response curves. Nystatin (600) 13 13.5 Cycloheximide (50) 41 43 Trifluoroperazineb (100) We determined the effect of the mutation on other membrane-associated enzyme activities. Two independent reactions, synthesis of chitin from UDP-GlcNAc and synthesis of squalene from farnesyl pyrophosphate, were measured. Trypsin-activated chitin synthase activity was unaffected by the mutation, and the IC50 for nikkomycin Z was also unchanged (1.6 pRg/ml for W303-1A; 2.1 jig/ml for R560-1C). The specific activity of squalene synthetase in mutant and wild-type membranes was 2 to 3 nmol * min-*mg of protein-, and the IC50s of zaragosic acid A were 0.2 and 0.3 nM, respectively. Of the three membrane-associated activities assayed in membranes from R560-1C, only the IC50 of L-733,560 was affected.
Genetics of echinocandin resistance. We performed a genetic analysis to determine if the pneumocandin resistance phenotype was due to a single gene mutation segregating in for haploid progeny from two tetrads (DYLIP3-7 and DYLIP4-6), the parents, and both heterozygous diploids are reported in Tables 3 and 4 . Whole-cell resistance segregated 2:2 in the tetrads, and the sensitivity of both diploids (YLIPD3 and YLIPD4) was intermediate between that of R560-1C and the sensitive parents. Whole-cell resistance data from 40 four-spore tetrads of R560-1C crossed with W303-1B confirmed these results (data not shown). Crude membrane fractions prepared from the haploid progeny of DYLIP3-7 and DYLIP4-6, as well as parental diploids, were challenged with fivefold dilutions of L-733,560 (Tables 3 and 4 ). The IC50s from these experiments illustrate that each resistant spore had resistant glucan synthase activity, while each sensitive spore had sensitive glucan synthase activity. Intermediate drug resistance in the diploid membrane preparations also reflects the whole-cell phenotype and demonstrates that the mutation is semidominant. The mutation that confers resistance to glucan synthase inhibitors is a single allele, which we have called etgl-1 for echinocandin target gene 1.
Drug stability in crude membrane fractions. Whole-cell and in vitro resistance to pneumocandins, particularly resistance resulting from a dominant or semidominant mutation, could be due to enhanced ability to degrade the inhibitor. The stability of L-733,560 in typical glucan synthase reaction mixtures from R560-1C and W303-1A was measured. In these experiments, the concentration of drug added (2 ,uM) was sufficient to inhibit wild-type synthesis by ca. 60% but inhibited the mutant Glucan synthase activity in crude microsomes can be separated into two fractions by extraction with NaCl and Tergitol NP-40 (29) . Each is inactive by itself, but reconstitution of the soluble and insoluble fractions produces an active complex. Table 5 shows that over 95% of the activity for crude microsomes from W303-1A and R560-1C is lost upon fractionation of the enzyme but that activity can be partially restored by recombining the fractions. Only the combination of a soluble fraction with an insoluble fraction reconstitutes activity (data not shown). Mixing fractions from the mutant and wild-type strains also restored activity; either insoluble fraction was functional with either soluble fraction. By titrating L-733,560 against the four different reconstituted enzymes, we determined the IC50s reported in Table 5 . Both complexes containing the mutant insoluble fraction were partially resistant, while those containing the mutant soluble fraction were fully sensitive to L-733,560.
Product analysis. We analyzed the radiolabeled material synthesized in glucan synthase reaction mixtures to determine if the etgl-J mutation altered the properties of the product. Typical chromatograms from W303-1A and R560-1C alkalisolubilized reaction mixtures separated on Superose 12 are shown in Fig. 6A . Two peaks of radioactivity, one in the void volume and one near the included volume, eluted from the column, and the profiles for the mutant and the wild type were equivalent. The late eluting peak was determined to be unincorporated UDP-[3H]glucose by thin-layer chromatography (data not shown). Several experiments suggest that the peak in the void volume is a product of the enzyme. First, chromatograms from reaction mixtures quenched before incubation by the addition of NaOH do not contain this peak. Second, the relative area of the void volume peak is consistent with our estimates, by TCA precipitation, of ca. 10% incorporation of glucose from UDP-glucose into product. Third, inhibition of R560-1C (B) . UDP-D-[6-3H] glucose was used, and the final specific activity was 5,600 dpm/nmol. The UDP-glucose concentration was titrated in twofold dilutions from 0.3 mM to 10 mM. The reaction velocity (M * min-109) was calculated and used to generate WoolfAugustinsson-Hofstee plots (50) . The Km for W303-1A was estimated at 1.1 mM, and the Vm. was 1.4 FM min. For R560-1C, the Km was 1.4 mM and the Vm. was 2.2 ,uM * minksynthesis by L-733,560 reduces the amount of TCA insoluble radioactivity in the reaction and the area of the void volume peak to an equivalent extent. Figure 6 also shows the radioactivity profile for reactions catalyzed in the presence or absence of 20 p.M L-733,560. The percentage of inhibition for duplicate reactions was measured by TCA precipitation. Weak inhibition of mutant activity (18%) and strong inhibition of wild-type activity (70%) are reflected in the reduction of the sizes of the respective product peaks.
The properties of the partially purified product from the R560-1C and W303-1A reaction mixtures were compared. Roughly 65% of the labeled product from both mutant and wild-type reaction mixtures was soluble at pH 2.4, while over 95% was soluble at pH 14. Authentic 1,3-,B-D-glucan (curdlan) had the same properties. The products from gel filtration were treated with laminarinase, a crude exo-1,3-p-D-glucanase. Over 95% of the material from both reaction mixtures was susceptible to digestion, as measured by TCA precipitation or chromatography on Superose 12. A single radiolabeled peak that eluted near the included volume was generated by digestion. This material was separated by HPLC anion-exchange chromatography as described in Materials and Methods, and fractions were assayed for radioactivity. The digestion product from both R560-1C and W303-1A eluted as a single peak that comigrated with authentic D-glucose (data not shown).
Other phenotypes of R560-1C. If glucan synthesis were impaired in R560-1C, the mutant cells might show phenotypic changes consistent with a defect in cell wall biosynthesis. Temperature sensitivity (43) , osmotic fragility (51), and hypersensitivity to exo-1,3-0-D-glucanase (44) are a few of the phenotypes described previously for cell wall mutants. Stationary-phase cultures of R560-1C and W303-1A were subcultured in rich medium, incubated at 25, 30, 37, and 420C, and plated for CFU. Both strains grew well at every temperature except 420C, where neither W303-1A nor R560-1C grew. Addition of 1 M sorbitol, an osmoticum which stabilizes strains with a weakened cell wall, did not enhance the growth rate of R560-1C; in fact, the mutant grew as well as W303-1A in all media tested, including minimal and rich broths. To test for exo-1,3-p3-D-glucanase sensitivity, fresh log-phase cultures of each strain were incubated with zymolyase and plated in medium with and without osmotic support and colonies were counted to determine the percentage of osmotically fragile cells. The concentrations of crude enzyme that reduced the number of viable cells by 2 logs were equivalent for both R560-1C and W303-1A. In these assays measuring cell wallrelated phenotypes, R560-1C was indistinguishable from W303-1A.
DISCUSSION
The S. cerevisiae mutant strain R560-1C has several properties that suggest that the etgl-1 mutation directly affects 1,3-3-D-glucan synthase activity. First, unlike those of any other mutants described to date, the in vitro enzyme activity of R560-1C is resistant to echinocandins. We have shown that the reaction has the properties previously reported for 1,3-p-Dglucan synthase (52) . The Km for UDP-glucose (1.1 mM for R560-1C, 3.8 mM for S. cerevisiae GS-1-36 [55] ) is within the range of values (0.7 to 7.1 mM) given for glucan synthases from several different fungi (16) , and the acid insolubility, base solubility, and laminarinase sensitivity of the product are comparable for W303-1A, R560-1C, and GS-1-36. Second, the phenotypes of enzyme and whole-cell resistance cosegregated in genetic crosses. Third, the level of enzyme resistance, as Eluted Volume (ml) Pneumocandin-resistant glucan synthase activity from R560-1C was unaffected in other properties we measured. The product synthesized by the mutant enzyme was indistinguishable from that of the wild type. Both polymers were alkalisoluble, partially acid-soluble polysaccharides with a high apparent molecular weight. The krel mutant described by Boone et al. (10) affected not only the level of cell wall 1,6-0-glucan but the structure as well. Analysis of the 1,6-13-glucan fraction isolated from a strain with a disruption of KRE1 showed that it had an altered structure with a smaller average polymer size. Our results illustrate that the mutant and wild-type polysaccharide products were equally sensitive to digestion with exo-1,3-13-D-glucanase, suggesting that the linkage between glucose units is exclusively 13-1,3. The mutation did not alter either the degree of polymerization or the overall structure of the polymer.
A surprising feature of the glucan synthesized in vitro is the apparent size of the polymer. We anticipated, on the basis of reports from Shematek et al. (52) , that the reaction product would be 60 to 80 glucose units in length. The product from W303-1A and R560-1C crude membranes elutes in the void volume of Superose 12, which suggests that the polymer length could be 3,000 glucose units or longer. Under the same elution conditions, curdlan, an authentic 1,3-13-D-glucan with a degree of polymerization estimated at 450 glucose units (56) , migrates as expected. The unexpected mobility of the in vitro product could be due to association with high-molecular-weight species ( Understanding the relationship between ETG1, KNR4, and HKR1 will further our understanding of 13-glucan synthesis, and direct demonstration of the role of the etgl-1-encoded protein in glucan synthesis awaits cloning and disruption of ETG1.
